Vindesine, a vinblastine derivative, began clinical trial in 1975. It has an antitumor spectrum in animals similar to that of vincristine, but with less neurotoxicity. Phase I trials of vindesine at Memorial Sloan-Kettering Cancer Center explored both a weekly and a daily x 5 dose schedule. A dose of 1.3 mg/m 2/day x 5-7 days every 3 weeks was well-tolerated. There were 2 measurable remissions in 6 heavily pretreated patients with testicular cancer. A phase II trial of vindesine in patients with germ-cell tumors who had failed to respond to conventional chemotherapy was begun in January 1977 and this is a report of the results.
|Original language||English (US)|
|Number of pages||3|
|Journal||Cancer Treatment Reports|
|State||Published - Dec 1 1979|
ASJC Scopus subject areas
- Cancer Research